2018年美国ASCO年会晚期乳腺癌内分泌治疗进展  

ASCO 2018: recent advances in endocrine therapy for advanced breast cancer

作　　者：石磊[1] 陈占红[1] 王晓稼[1] Lei Shi;Zhanhong Chen;Xiaojia Wang(Department of Breast Medical Oncology,Zhejiang Cancer Hospital,Hangzhou 310022,China)

机构地区：[1]浙江省肿瘤医院乳腺肿瘤内科,杭州市310022

出　　处：《中国肿瘤临床》2018年第18期919-921,共3页Chinese Journal of Clinical Oncology

摘　　要：内分泌治疗是晚期乳腺癌治疗的主要手段之一,近年来内分泌治疗新药物以及内分泌治疗耐药均为临床研究关注的热点。本文将2018年美国ASCO会议晚期乳腺癌内分泌治疗的进展进行概述。Hormone therapy plays a very important role in advanced breast cancer treatment.In recent years,there has been an increased focus on developing novel endocrine treatment strategies involving new drugs for treatment of endocrine-resistant breast cancer.This review summarizes recent advances in hormone therapy for advanced breast cancer in the American Society of Clinical Oncology Annual Meeting 2018.

关 键 词：晚期乳腺癌 内分泌治疗 ASCO 

分 类 号：R737.9[医药卫生—肿瘤]